Adamis Pharmaceuticals Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Eboo Versi

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.5yrs

Recent management updates

Recent updates

CEO

Eboo Versi (70 yo)

less than a year

Tenure

Dr. Ebrahim Versi, also known as Eboo, M.D., Ph D., is Chief Executive Officer and Chair of the Board at Adamis Pharmaceuticals Corporation since May 25, 2023. He had been Chief Executive Officer and Direc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Marguglio	Co-Founder	1.3yrs	US$526.35k	no data
Ebrahim Versi	CEO & Chair of the Board	less than a year	no data	no data
Jennifer Suski	Senior Director of Marketing	8.8yrs	no data	no data
Eddie Glover	Chief Executive Officer of US Compounding Inc	no data	no data	no data
Robert Rothermel	Consultant	no data	US$92.34k	no data

1.3yrs

Average Tenure

71.5yo

Average Age

Experienced Management: CY3's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Ebrahim Versi	CEO & Chair of the Board	less than a year	no data	no data
Howard Birndorf	Independent Director	4yrs	US$64.00k	no data
Vickie Reed	Independent Director	1.3yrs	US$47.18k	no data
Meera Desai	Independent Director	1.8yrs	US$64.00k	no data
Jannine C. Versi	Director	no data	no data	no data

1.5yrs

Average Tenure

61yo

Average Age

Experienced Board: CY3's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Adamis Pharmaceuticals Management

Management criteria checks 0/4

Key information

Recent management updates

DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024

DMK Pharmaceuticals Corporation Announces CFO Changes

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023

Adamis Pharmaceuticals Corporation Announces Chief Financial Officer Changes

Adamis Pharmaceuticals Corporation Appoints Vickie Reed to Board of Directors

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Recent updates

Nasdaq to Delist Common Stock of DMK Pharmaceuticals

DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index

DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024

DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI

Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index

DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock Market

DMK Pharmaceuticals Corporation Announces CFO Changes

DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirements

Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023

Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.

Adamis Pharmaceuticals Corporation Announces Chief Financial Officer Changes

Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023

Adamis Pharmaceuticals Corporation to Report Q3, 2022 Results on Nov 14, 2022

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceutics Corporation Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

Adamis Pharmaceuticals Corporation to Report Q2, 2022 Results on Aug 10, 2022

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of Covid-19

Adamis Pharmaceuticals Corporation announced that it has received $0.3 million in funding from Lincoln Park Capital, LLC

Adamis Pharmaceuticals Corporation Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation Appoints Vickie Reed to Board of Directors

Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

Adamis Pharmaceuticals Corporation to Report Q1, 2022 Results on May 16, 2022

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Richard C. Williams Notifies Adamis Pharmaceuticals Corporation That Effective April 15, 2022, He Will Be Retiring

Adamis Pharmaceuticals Corporation’S Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

Adamis Pharmaceuticals Corporation Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Corporation Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Adamis Pharmaceuticals Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 Mg Intramuscular Dose of Naloxone in Zimhi™

Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements

Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

Adamis Pharmaceuticals Receives A Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

An unknown buyer completed the acquisition of U.S. Compounding, Inc. from Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) for $15 million.

Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19

Adamis Provides Update on ZIMHI™

Adamis Highlights National Institute of Health Study Identifying Tempol as a Potential Antiviral Drug for COVID-19

Adamis Pharmaceuticals Announces Receipt of Deficiency Letter from NASDAQ

Adamis Pharmaceuticals Corporation announced delayed amended 10-Q filing

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

Adamis Pharmaceuticals Corporation announced delayed annual 10-K filing

Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the Covid-19 Challenged Hamster Model

Adamis Pharmaceuticals Corporation Clears to Proceed with Human Studies of Tempol for the Treatment of COVID-19

Adamis Pharmaceuticals Strengthens Patent Portfolio for its Naloxone Product Candidate

Adamis Pharmaceuticals Corporation has completed a Follow-on Equity Offering in the amount of $44.999999 million.

Adamis Pharmaceuticals Corporation Announces the Availability of SYMJEPI Products in the Walgreens Prescription Savings Club

Adamis Pharmaceuticals Receives Complete Response Letter from the FDA Regarding ZIMHI

Adamis Pharmaceuticals Corporation to Report Q3, 2020 Results on Nov 09, 2020

Adamis Pharmaceuticals Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Adamis Pharmaceuticals Corporation has completed a Follow-on Equity Offering in the amount of $10 million.

Adamis Pharmaceuticals Corporation announced that it has received funding from Matrix Biomed Inc.

Adamis Pharmaceuticals Corporation Contemplates Bankruptcy

Adamis Pharmaceuticals Corporation announced delayed 10-Q filing

Adamis Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from Russell Microcap Growth Index

Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from Russell Microcap Value Index

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age